Geron Corporation (GERN)

Currency in USD
1.4400
-0.1100(-7.10%)
Closed·
1.4600+0.0200(+1.39%)
·
GERN is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1.42001.5400
52 wk Range
1.04002.0100
Key Statistics
Prev. Close
1.55
Open
1.51
Day's Range
1.42-1.54
52 wk Range
1.04-2.01
Volume
21.18M
Average Volume (3m)
12.44M
1-Year Change
-13.253%
Book Value / Share
0.35
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
GERN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
3.4000
Upside
+136.11%
Members' Sentiments
Bearish
Bullish
ProTips
High shareholder yield

Geron Corporation News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Geron Corporation Company Profile

Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. It offers RYTELO a telomerase inhibitor for the treatment f adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia. The company was incorporated in 1990 and is headquartered in Foster City, California.

Geron Corporation SWOT Analysis


Oncology Frontrunne
Geron's Rytelo shows promise in MDS and MF treatment, with consistent efficacy across patient groups and a favorable safety profile
Market Challenges
Despite Q1 sales shortfall, Geron sees renewed growth. Analysts project profitability by 2H 2025, but inventory issues and competition pose risks
Expansion Potential
EU approval could boost Geron's global presence. Label expansion for Imetelstat, particularly in myelofibrosis, presents significant growth opportunities
Analyst Outlook
Price targets range from $4 to $9, reflecting varied perspectives on Geron's future. The company's path to profitability remains a key focus for investors
Read full SWOT analysis

Geron Corporation Earnings Call Summary for Q4/2025

  • Geron Q4 2025 EPS of -$0.05 missed forecast of -$0.03; revenue of $48.02M fell short of $50.76M estimate, triggering 20.5% stock plunge.
  • Full-year 2025 revenue surged 142% to $184M from $76M in 2024, driven by strong commercial performance of lead therapeutic RYTELO.
  • Cash position declined to $400M from $503M year-over-year, raising potential liquidity concerns amid competitive hematology market pressures.
  • Company projects 2026 operating expenses of $230M-$240M with strategic restructuring focused on expanding RYTELO's market presence and growth.
  • Management emphasizes refined commercial strategy to strengthen RYTELO's position, though analysts question ability to meet targets after Q4 shortfall.
Last Updated: 2026-02-25, 08:52 a/m
Read Full Transcript

Compare GERN to Peers and Sector

Metrics to compare
GERN
Peers
Sector
Relationship
P/E Ratio
−11.0x−6.9x−0.5x
PEG Ratio
−0.220.110.00
Price/Book
4.1x2.7x2.6x
Price / LTM Sales
5.0x14.5x3.2x
Upside (Analyst Target)
158.1%109.2%50.1%
Fair Value Upside
Unlock17.9%8.6%Unlock

Analyst Ratings

4 Buy
1 Hold
1 Sell
Ratings:
6 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 3.4000
(+136.11% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
TD Cowen
Buy3.00+108.33%4.00MaintainJan 29, 2026
H.C. Wainwright
Hold---MaintainDec 12, 2025
H.C. Wainwright
Hold---MaintainDec 09, 2025
Leerink Partners
Buy2.00+38.89%3.00MaintainNov 05, 2025
Goldman Sachs
Sell1.00-30.56%-New CoverageJul 10, 2025

Earnings

Latest Release
Feb 25, 2026
EPS / Forecast
-0.05 / -0.03
Revenue / Forecast
48.02M / 50.76M
EPS Revisions
Last 90 days

GERN Income Statement

People Also Watch

23.920
CPRX
+0.17%
186.74
JAZZ
-1.95%
4.80
RCKT
-3.42%
38.31
BAYGN
-5.66%

FAQ

What Is the Geron (GERN) Stock Price Today?

The Geron stock price today is 1.4400 USD.

What Stock Exchange Does Geron Trade On?

Geron is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Geron?

The stock symbol for Geron is "GERN."

What Is the Geron Market Cap?

As of today, Geron market cap is 931.9900M USD.

What Is Geron's Earnings Per Share (TTM)?

The Geron EPS (TTM) is -0.1287.

When Is the Next Geron Earnings Date?

Geron will release its next earnings report on May 11, 2026.

From a Technical Analysis Perspective, Is GERN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Geron Stock Split?

Geron has split 0 times.

How Many Employees Does Geron Have?

Geron has 229 employees.

What is the current trading status of Geron (GERN)?

As of Mar 04, 2026, Geron (GERN) is trading at a price of 1.4400 USD, with a previous close of 1.5500 USD. The stock has fluctuated within a day range of 1.4200 USD to 1.5400 USD, while its 52-week range spans from 1.0400 USD to 2.0100 USD.

What Is Geron (GERN) Price Target According to Analysts?

The average 12-month price target for Geron is 3.4000 USD, with a high estimate of 5 USD and a low estimate of 1 USD. 4 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +136.11% Upside potential.

What Is the GERN Premarket Price?

GERN's last pre-market stock price is 1.5600 USD. The pre-market share volume is 104,430.0000, and the stock has decreased by 0.0100, or 0.6500%.

What Is the GERN After Hours Price?

GERN's last after hours stock price is 1.4600 USD, the stock has decreased by 0.0200, or 1.3900%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.